Clinical Report: CURE Framework for Managing Chronic Inflammation

Overview

Expand on the types of immune-mediated conditions and how mechanistic evidence informs personalized interventions.

Background

Chronic inflammation is a key factor in immune-mediated diseases, often leading to persistent and relapsing conditions. Current treatments frequently focus on reactive symptom management, which can result in relapse upon therapy discontinuation. A structured, phase-based approach like CURE is essential for improving long-term outcomes in patients with chronic inflammatory diseases.

Data Highlights

Key Findings

• The CURE framework consists of three phases: CONTROL, UNLOAD and RESET, and EQUILIBRATE.
• CONTROL phase involves intensive induction therapy to suppress inflammatory circuits.
• UNLOAD and RESET focus on guided de-escalation to consolidate remission.
• EQUILIBRATE aims for proactive maintenance to stabilize immune equilibrium.
• Durable disease control may depend on therapeutic exposure sufficient to suppress feedback-driven immune networks.
• The framework is applicable across various conditions, including atopic dermatitis, psoriasis, and rheumatoid arthritis.

Clinical Implications

Healthcare professionals should consider adopting the CURE framework to guide treatment strategies for chronic inflammatory diseases. This approach emphasizes the importance of phase-specific interventions and proactive management to enhance long-term patient outcomes.

Conclusion

The CURE framework offers a novel perspective on managing chronic inflammation, shifting the focus from reactive treatment to proactive, phase-specific strategies. This model may improve disease control and reduce relapse rates in patients.

Related Resources & Content

1. Journal of Gastroenterology, Current Advances in the Management of Crohn’s Disease, 2018 -- https://link.springer.com/article/10.1007/s00535-018-1479-6
2. The Journal of Infectious Diseases, Evolving Approaches in Infectious Disease Management: The Role of Host-Directed Therapies for Future ID Specialists, 2023 -- https://academic.oup.com/jid/article/233/2/230/8263033
3. The New Gastroenterologist, Tailored Medicine Strategy Enhances Infliximab Efficacy in Chronic Inflammatory Bowel Disease, 2025 -- https://news.gastro.org/issues/2025/may/precision-medicine-approach-improves-ibd-infliximab-outcomes/
4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update - ScienceDirect -- https://www.sciencedirect.com/science/article/pii/S0003496726000750?utm_source=openai
5. The updated 2025 ACG guidelines to manage adult ulcerative colitis patients - American College of Gastroenterology -- https://gi.org/journals-publications/ebgi/alkazzi_aug2025/?utm_source=openai
6. The ASCO Post — Defining a Cure for Chronic Myeloid Leukemia and Strategies to Achieve this Goal
7. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update - ScienceDirect
8. The updated 2025 ACG guidelines to manage adult ulcerative colitis patients - American College of Gastroenterology
9. Medical management of inflammatory bowel diseases | The BMJ